



SOLARA
Active Pharma Sciences

Communication Address :

Solara Active Pharma Sciences Limited

Corporate office - 2nd floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post),
Chennai - 600 127, India
Tel : +91 44 4344 6700
Fax : +91 44 4740 6190
E-mail : info@solara.com
www.solara.co.in

March 9, 2022

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) – Change in Key Managerial Personnel of the Company

Pursuant to Regulation 30 read with Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**LODR Regulations**"), we wish to inform you that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on March 9, 2022.

Name of the Director	Resignation / Appointment
Mr. Subhash Chand Anand (DIN: 07348933)	Resigned as Executive Director & Chief Financial Officer (ED & CFO) and Director of the Company.
Mr. S. Hariharan	Appointed as Chief Financial Officer of the Company.

Please note that the relevant details regarding the change in key managerial personnel required to be disclosed under the SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed herewith in the annexure to this letter. Also find attached press release on appointment Mr. S. Hariharan as Chief Financial Officer. We request you to take the same on record.

Thanking you,

Yours faithfully,

For Solara Active Pharma Sciences Limited


S. Murali Krishna
Company Secretary

Encl: As above.



ANNEXURE

Name of Director	Mr. Subhash Chand Anand (DIN: 07348933)
Reason for change, viz, resignation	Mr. Subhash has tendered his resignation as Executive Director & CFO and Director of the Company to pursue interests outside Solara.
Date of cessation	The resignation is effective from March 9, 2022
Brief profile	Not Applicable
Disclosure of relationship between directors	Not Applicable

Name of Key Managerial Personnel	Mr. S. Hariharan
Reason for change, viz, appointment	Consequent to the resignation of Mr. Subhash Chand Anand as Executive Director and CFO of the Company, the Board of Directors of the Company, pursuant to the recommendation by the Nomination and Remuneration Committee, approved the appointment of Mr. S. Hariharan as Chief Financial Officer (CFO) of the Company with effect from March 9, 2022.
Date of appointment	The appointment is effective from March 9, 2022.
Term of Appointment	Not Applicable
Brief profile	Hariharan is a Cost Accountant with rich and varied experience of more than 30 years in field of Corporate Finance, Accounts and Strategic planning. He played a very important role in the merger process of Shasun with Strides during 2014 and 2015. Also in demerger process of Strides, SeQuent and Solara during 2017 and 2018. He has rich experience in the fields of Finance, Accounts, Secretarial, Taxation, Legal and Information Technology functions. He has extensive experience in Mergers and Acquisitions.
Disclosure of relationship between directors	Mr. S. Hariharan is not related to any Director of the Company.

Solara announces the return of Hariharan Subramaniam as its new CFO

Bangalore, March 9, 2022: Solara Active Pharma Sciences Limited (Solara), one of India's leading pure-play active pharmaceutical ingredients companies, today announced the return of **Hariharan Subramaniam(Hari) as the new Chief Financial Officer (CFO)** with immediate effect.

Hari was part of the Solara since its inception and played an instrumental role in driving the growth and profitability of the Company. In his current position, he will be responsible for Finance, legal, secretarial, IT, and other workstreams and will be part of Solara's Executive Leadership Team. The Board believes that Hari's rich experience in the pharmaceutical sector would be valuable for driving the rebound of the Company.

Hari will succeed Subhash Anand (Subhash), the incumbent CFO and Executive Director of the Company, who has decided to pursue opportunities outside Solara. The Board acknowledged Subhash's decision and thanked him for his contributions to the Company over the last two years.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA), headquartered in Bengaluru, India, offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five globally compliant API facilities, with approvals including the USFDA, EU GMP, and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal

✉ abhishek.singhal@solara.co.in

☎ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.